Exploring Cagrilintide: The Long-Acting Amylin Analog Shaping Metabolic Research

At M5 Research Peptides, we’re committed to equipping laboratories, academic institutions, and biotech innovators with high-purity research compounds that drive scientific discovery. One peptide generating significant interest in metabolic, obesity, and endocrinology research is cagrilintide — a synthetic, long-acting analogue of human amylin.

Whether you’re investigating appetite regulation, gastric motility, glucagon dynamics, or synergistic effects with GLP-1 pathway compounds, cagrilintide offers a powerful tool for in vitro and in vivo studies. This detailed guide covers its origins, mechanism, key research findings, and why researchers nationwide choose M5 for their cagrilintide needs.

What Is Cagrilintide?

Cagrilintide (CAS 1415456-99-3) is a 37-amino-acid peptide engineered as a long-acting amylin analogue and dual amylin/calcitonin receptor agonist (DACRA). Natural amylin is co-secreted with insulin from pancreatic beta cells and plays a critical role in postprandial glucose control and satiety signaling. However, native amylin has a very short half-life due to rapid enzymatic degradation and fibril formation.

Cagrilintide overcomes these limitations through targeted structural modifications:

• Acylation with a C20 fatty acid chain (similar to semaglutide) for albumin binding and extended circulation.
• Specific amino acid substitutions (e.g., 14E/17R salt bridge, proline residues at positions 25/28/29, and C-terminal proline) to enhance stability, reduce aggregation, and optimize receptor binding.

The result is a compound with a plasma half-life of approximately 7–8 days, enabling once-weekly subcutaneous administration in research protocols — a major advantage for long-term metabolic studies.

Important Disclaimer: Cagrilintide is sold by M5 Research Peptides strictly for laboratory research use only. It is not for human or veterinary consumption, not evaluated by the FDA for safety or efficacy, and not intended to diagnose, treat, or prevent any disease.

Mechanism of Action: Targeting Amylin Pathways for Satiety and Metabolism

Cagrilintide binds with high affinity to amylin receptors (AMY1R, AMY2R, AMY3R — heterodimers of the calcitonin receptor and receptor activity-modifying proteins RAMP1–3) and the calcitonin receptor itself. Key research-supported effects include:

• Central satiety signaling: Activates neurons in the area postrema (AP) and projects to the lateral parabrachial nucleus and other homeostatic/hedonic brain regions, reducing food intake without affecting lean mass proportionally in preclinical models.
• Delayed gastric emptying: Prolongs nutrient absorption, contributing to reduced caloric intake and improved postprandial glucose control.
• Glucagon suppression: Inhibits postprandial glucagon release from alpha cells.
• Synergistic potential: Complements GLP-1 receptor agonists (like semaglutide) by acting through distinct but overlapping pathways — amylin primarily via brainstem circuits, GLP-1 via hypothalamic and vagal routes.

These multi-target actions make cagrilintide especially valuable for researchers studying complex metabolic disorders where single-pathway interventions fall short.

Development History and Research Milestones

Developed by Novo Nordisk, cagrilintide emerged from efforts to create stable, long-acting amylin mimetics. Early work (published in the Journal of Medicinal Chemistry, 2021) detailed its design for weekly dosing and non-selective receptor agonism.

Key preclinical and early clinical data:

• Demonstrated dose-dependent weight reduction and improved cardiometabolic markers in rodent and primate models.
• Phase 1b combination studies (2021) confirmed no pharmacokinetic interference with semaglutide 2.4 mg.

Landmark Clinical Research Findings (for Informational Purposes Only)

While M5 supplies cagrilintide exclusively for non-human research, the broader scientific literature provides context for experimental design:

Mono-Therapy Phase 2 (2021, The Lancet) In 706 adults with overweight or obesity, once-weekly cagrilintide (0.3–4.5 mg) + lifestyle intervention produced 6.0–10.8% body weight reduction at 26 weeks (vs. 3.0% placebo and 9.0% liraglutide 3.0 mg). The 4.5 mg dose was statistically superior to liraglutide. Weight loss continued beyond the typical plateau seen with placebo, and triglyceride/VLDL reductions were notable.

Combination Therapy (CagriSema = cagrilintide + semaglutide) Phase 2 data showed additive effects:

• Up to 17.1% weight loss at 20 weeks with cagrilintide 2.4 mg + semaglutide 2.4 mg (vs. 9.8% semaglutide + placebo).
• Greater improvements in lipids, blood pressure, and glycemic parameters.

Phase 3 REDEFINE Program (2025 data, NEJM & ADA presentations)

• REDEFINE 1 (obesity/overweight, n=3,417): CagriSema 2.4 mg/2.4 mg → 20.4% mean weight loss at 68 weeks (vs. 11.5% cagrilintide alone, 14.9% semaglutide alone, 3.0% placebo). Over 60% of participants achieved ≥20% loss.
• REDEFINE 2 (obesity + type 2 diabetes): 13.7% weight loss vs. 3.4% placebo, with superior HbA1c reductions.
• Additional 2026 REIMAGINE 2 topline: CagriSema outperformed semaglutide monotherapy in both HbA1c (−1.91 vs. −1.76 percentage points) and weight loss (14.2% vs. 10.2%).

These outcomes highlight cagrilintide’s potential as both a standalone research tool and in combination protocols.

Safety Profile in Published Studies Gastrointestinal events (nausea, vomiting, diarrhea, constipation) were the most common, typically mild-to-moderate and transient during dose escalation. Injection-site reactions were dose-dependent but generally manageable. No new safety signals emerged beyond those expected from the amylin/GLP-1 class.

Research Applications for Cagrilintide

Laboratories are actively exploring:

• Appetite and feeding behavior models
• Synergistic peptide combinations (CagriSema-style blends)
• Cardiometabolic endpoints (lipids, blood pressure, inflammation)
• Receptor pharmacology and signaling (cAMP, phosphoproteomics in kidney tubules, etc.)
• Long-term metabolic adaptation and weight maintenance studies

Final Thoughts: The Future of Amylin Research Starts Here

Cagrilintide represents a new chapter in peptide-based metabolic research — moving beyond single-hormone approaches toward multi-receptor strategies that more closely mimic human physiology. As phase 3 programs advance and combination data continue to impress, demand for high-quality research-grade cagrilintide will only grow.

Ready to incorporate cagrilintide into your next study?

Browse our cagrilintide selection at M5 Research Peptides or contact our team for bulk pricing, COA requests, or protocol recommendations.

M5 Research Peptides — Purity you can trust. Results you can publish.

All products are for research use only. Not for human consumption. Always consult your institutional review board and follow all applicable regulations.